The CardioVascular Research Foundation (CRF) proudly organizes Technology and Heart Failure Therapeutics (THT) 2024.

This conference offers a unique perspective by uniting device- and technology-based therapies with drug-based approaches, effectively bridging gaps in current practices. Attendees can expect comprehensive updates on the status of treatments for heart failure, spanning drug and device solutions, LV ejection fractions, and the latest pivotal studies yet to be published or included in guidelines.

THT 2024 immerses participants in cutting-edge innovations that can be directly applied in heart failure treatment. Additionally, the conference provides a forward-looking outlook on the heart failure therapeutics pipeline, focusing on emerging technologies (drugs, devices, monitoring strategies) in clinical trials. It also delves into the transformative role of artificial intelligence and machine learning in the care of heart failure patients.

Join THT 2024 for a forward-thinking exploration of the future of heart failure treatment and gain valuable insights into the latest developments in this dynamic field.